Group 1 - Walgreens Boots Alliance shares increased by 7.6% amid reports of a potential take-private deal with Sycamore Partners [1][4] - The proposed deal price is between $11.30 and $11.40 per share, with financing from major banks being arranged [2][4] - Sycamore's plans may involve breaking Walgreens into three separate entities, each with distinct capital structures [3][5] Group 2 - The stock price has fluctuated significantly, trading as low as the low $8 range in December and nearly $13 in early January [6] - Current trading price is $11.02, indicating limited upside potential for investors, particularly for those not engaged in merger arbitrage [5][7] - The deal is not finalized, and there is a risk of talks faltering, which could lead to a significant drop in stock price if the deal collapses [5][7]

Walgreens Boots Alliance is on the verge of finalizing a deal with private-equity firm Sycamore Partners to take the embattled drugstore chain private in a transaction valued at approximately $10 billion, according to a report.Negotiations are in advanced stages, with both sides aiming to seal the agreement as soon as Thursday — though a last-minute hurdle could still delay or derail talks, sources told the Wall Street Journal. The deal is expected to involve Sycamore paying between $11.30 and $11.40 per sh ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

 Walgreens Boots Alliance Inc (NASDAQ:WBA) was last seen up 7.1% at $10.99, amid news the embattled drugstore giant is nearing a $10 billion deal with private equity firm Sycamore Partners that would take it private, possibly as soon as Thursday. Per the Wall Street Journal, the firm would keep the core U.S. retail business and sell off or take public other parts of the company. Since the start of 2025, WBA is up 17.8%, cutting into its now 46.6% year-over-year deficit. The stock's record high of $97.30 was ...

Core Viewpoint - Walgreens is nearing a $10 billion deal to go private, which has resulted in an increase in its stock price [1] Group 1: Company Overview - The potential deal indicates a significant shift in Walgreens' strategy, moving towards privatization [1] - The stock price of Walgreens has risen in response to the news of the impending deal [1] Group 2: Financial Implications - The deal is valued at approximately $10 billion, highlighting the scale of the transaction [1] - The privatization could lead to changes in operational focus and financial restructuring for Walgreens [1]

Group 1 - Walgreens Boots Alliance Inc. is nearing a $10 billion deal to sell itself to Sycamore Partners, a private-equity firm [1] - The deal would result in Walgreens being taken private and likely broken up [1] - The potential announcement of the deal could occur as soon as Thursday [1]

Group 1: Logitech International SA (LOGI) - LOGI shares are down 2.9%, trading at $98.24, following a downgrade to "underperform" from "neutral" by BofA Global Research due to recent struggles and tariff threats [1][2] - The stock recently attempted to break its three-year high of $105.65 but closed below its 20-day moving average for the first time since January, despite an 18.8% increase so far in 2025 [2] - Options traders are showing bullish sentiment with a 50-day call/put volume ratio of 31.05, which is higher than 98% of annual readings [3] Group 2: Walgreens Boots Alliance Inc (WBA) - WBA shares are down 3.8%, trading at $10.81, following a downgrade to "sell" from "hold" by Deutsche Bank due to high uncertainty, and the stock has a year-over-year deficit of 49.7% [1][3] - Despite a 15.5% year-to-date gain, WBA has faced overhead pressure at the $12 level, capping rallies since late January [3] - Options activity is notably bullish, with 28,000 calls traded, which is double the intraday average volume, compared to only 5,051 puts [4]

Walgreens Boots Alliance (WBA) ended the recent trading session at $11.23, demonstrating a +1.72% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 1.59% for the day. Elsewhere, the Dow saw a downswing of 0.45%, while the tech-heavy Nasdaq depreciated by 2.78%.Prior to today's trading, shares of the largest U.S. drugstore chain had lost 1.87% over the past month. This has lagged the Retail-Wholesale sector's gain of 0.87% and was narrower than the S&P 5 ...

Shares of Walgreens Boots Alliance (WBA 1.72%) rose on Thursday, up as much as 7.3% before settling into a 2.2% gain by 3:30 p.m. ET. That gain was still notable, since the broader markets were down significantly on the day.News reports circulated with further details on a potential buyout of the company by private equity firm Sycamore Partners, which has been in talks to buy the troubled pharmacy since late 2024.A potential three-way splitAccording to people familiar with the matter and reported in the Fin ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by March 31, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [4] Group 3: Case Allegations - The lawsuit alleges that Walgreens failed to disclose widespread violations of federal law regarding prescription medication dispensation and reimbursement during the Class Period [5] - It is claimed that Walgreens' conduct posed a risk of regulatory scrutiny, civil liability, and reputational harm, and that its revenue from prescription sales was unsustainable due to unlawful practices [5] - The lawsuit asserts that Walgreens' public statements were materially false and misleading, leading to investor damages when the truth was revealed [5]